Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular
Biotech
US VC launches another biotech with China-licensed asset
Aditum is offering up to $1 billion biobucks to Mabwell for exclusive global licensing rights to a dual-target siRNA candidate.
Gabrielle Masson
Sep 17, 2025 10:30am
Novartis spends $1.4B for Tourmaline, CV med that wowed in ph. 2
Sep 9, 2025 4:28am
Novartis returns to Argo for $5B cardiovascular collab
Sep 3, 2025 9:15am
Roche's $50B US investment to include upcoming Boston CVRM site
Apr 22, 2025 5:10am
Merck & Co. pens $200M upfront deal for Hengrui med
Mar 25, 2025 9:10am
Roche to house its CVRM research work at new Boston hub
Mar 7, 2025 9:40am
